Angsuman Chakraborty21 Oct 2008 03:40 am
In what can be called breakthrough in the both stem cell and cancer study, the Cell Therapeutics, Inc today announced successful result of a innovative study that investigated high (bone marrow ablative) dose Zevalin(R) ([90Y]-ibritumomab tiuxetan) followed by autologous stem cell infusions among 30 patients.
All these patients were with relapsed/refractory or high risk aggressive non-Hodgkin’s lymphoma (NHL) not eligible for a chemotherapy-based transplant. In this study, three cycles of conventional chemotherapy were given followed by high dose chemotherapy with a stem cell rescue and then followed by up to three times the standard dose of Zevalin with an additional stem cell rescue. This treatment regimen resulted in 83 percent of patients achieving a disease free state with a projected overall survival of 87 percent after a median follow up of 30 months.
About Non-Hodgkin’s Lymphoma
Non-Hodgkin’s lymphoma (NHL) is caused by the abnormal proliferation of white blood cells and normally spreads through the lymphatic system, a system of vessels that drains fluid from the body. NHL can be broadly classified into two main forms — aggressive NHL, a rapidly spreading acute form of the disease, and indolent NHL, which progresses more slowly. According to the National Cancer Institute’s SEER database there were nearly 400,000 people in the U.S. with NHL in 2004. The American Cancer Society estimates that 66,120 people will be diagnosed with NHL in 2008 and more than 19,000 are expected to die.
Source: MarketWatch
Filed under Cancer, Stem Cell | Comment Below
Related?
Stem cell transplantation shows ray of hope in AIDS-related LymphomaApril 16th, 2009 European researchers Dr. Jose L. Diez-Martin of Hospital General Universidad Gregorio Maranon, Madrid, Spain, and colleagues claimed that HIV-positive people with high-grade lymphoma can be treated safely and effectively by autologous stem cell transplantation(ASCT).
AML (Cancer) Treatment With Allogeneic Stem Cell Transplants Shows Strong Promise in AdultsNovember 6th, 2005 Researchers from Marseille in France have reported a 76% 2-year, leukemia-free survival in 33 adults (median age of 52 years; oldest 60 years) with acute myeloid leukemia (AML) and treated with a reduced-intensity allogeneic stem cell transplant? after remission induction and consolidation. The details of this phase II study appeared in the November 1, 2005, issue of Cancer.
Stem Cell Research Provides Help for Children With High-Risk Brain TumorsSeptember 11th, 2006 Scientists report they have come up with a new treatment for children with brain tumors called medulloblastomas. Children with the high-risk tumors have a low 30-40 percent chance of surviving and living to the age of 5 and chemotherapy can take as long as a year.
Stem cell treatment is the choice for Sauk County Commissioner to kill his cancerMay 6th, 2009 Stearns County Commissioner Don Otte who never bow down to cancer, recently underwent a stem cell transplant to give a great boost to his 16-year old battle with non-Hodgkins lymphoma. Otte, now 63, was diagnosed with non-Hodgkins lymphoma in 1992, doctors told him he would die with in five years.
Mantle cell Lymphoma can be cured by stem cell therapyAugust 27th, 2008 Recent news reveals the cure mantle cell lymphoma with stem cell transplant associated with intensive immuno-chemotherapy. Mantle cell lymphoma (MCL) is a subset of non-Hodgkin’s lymphoma that is characterized by diffuse lymph node involvement, advanced stage of cancer at diagnosis, bone marrow involvement, and lymphoma cancer cells in the blood
Two related trials was carried out by the Researchers affiliated with the Nordic Lymphoma Group and Researchers from Emory University.
Umbilical Cord Blood Transplants Successful in Children with High-Risk Acute Lymphocytic LeukemiaJuly 16th, 2005 Researchers from Northwestern University have shown that children with high-risk acute lymphocytic leukemia (ALL) receiving umbilical cord blood transplants have similar outcomes to patients receiving related allogeneic stem cell transplants. The details of this comparative study were presented at the Third Annual International Umbilical Cord Blood Transplantation Symposium in Los Angeles, Calif., June 3-4, 2005.
Autologous stem cell transplant could enhance pediatric brain tumor treatment effectivelyMay 29th, 2009 Researchers from Los Angeles Children Hospital claimed that autologous stem cell transplant along with radiation and chemotherapy help improve the survival rates of the children with average and high-risk Medulloblastoma (MB). Medulloblastoma is a relatively rare brain tumor in children and has a grave prognosis.
Anti-HIV genes can be used for potential HIV treatmentDecember 9th, 2008 In a major breakthrough in both stem cell research and HIV treatment, the US researchers finds Anti-HIV genes can be introduced into autologous peripheral blood progenitor cells, resulting in a potentially HIV-resistant treatment. Autologous stem cell transplantation is viable treatment for relapsed or high risk ARL.
Leave a Comment
